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 Abstract 
 Background: One-month dual antiplatelet treatment, with aspirin and clopidogrel, following 
internal carotid artery stent placement is the current standard of care to prevent in-stent 
thrombosis. Cilostazol, an antiplatelet drug, has been demonstrated to have a safety profile 
comparable to aspirin and clopidogrel.  Objective: To evaluate the safety and clinical efficacy 
of cilostazol and aspirin therapy following internal carotid artery stent placement up to 1 
month postprocedure.  Methods: A phase I open-label, nonrandomized two-center prospec-
tive study was conducted. All subjects received aspirin (325 mg/day) and cilostazol (200 mg/
day) 3 days before extracranial stent placement. Two antiplatelet agents were continued for 
1 month postprocedure followed by aspirin daily monotherapy. The primary efficacy end 
point was the 30-day composite occurrence of death, cerebral infarction, transient ischemic 
attack, and in-stent thrombosis. The primary safety end point was bleeding.  Results: Twelve 
subjects (mean age ± SD, 66 ± 12 years; 9 males) were enrolled and underwent internal ca-
rotid artery angioplasty and stent placement. None of the subjects who successfully followed 
the study protocol experienced any complications at the 1- and 3-month follow-ups. One pa-
tient had a protocol deviation due to concurrent use of enoxaparin (1 mg/kg twice daily) in 
addition to aspirin and cilostazol, resulting in a fatal symptomatic intracerebral hemorrhage 
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following successful stent placement on postprocedure day 1. One patient discontinued cilo-
stazol after the first dose secondary to dizziness.  Conclusion: The use of cilostazol and aspi-
rin for internal carotid artery stent placement appears to be safe, but protocol compliance 
needs to be emphasized.  © 2016 S. Karger AG, Basel 
 Introduction 
 Cilostazol, an antiplatelet medication different from aspirin and clopidogrel, selectively 
inhibits phosphodiesterase III, increases intraplatelet intracellular cyclic 3 ′ -5 ′ -adenosine 
monophosphate levels, activates protein kinase A, and decreases intracellular calcium levels 
 [1, 2] . The antiplatelet effect of cilostazol, a prodrug, begins after it is hepatically metabolized. 
It has been demonstrated to have pleiotropic effects, reducing smooth muscle proliferation 
and intimal hyperplasia and causing vasodilation  [3–5] . Cilostazol, also known as Pletal, has 
been approved in the United States since 1999 for the treatment of symptomatic peripheral 
arterial disease  [6] . The Cilostazol Stroke Prevention Study (CSP 2) demonstrated that cilo-
stazol (200 mg/day) was associated with fewer incidence of hemorrhagic events compared 
to aspirin (81 mg/day) for the prevention of stroke after an initial ischemic stroke (1.2 vs. 
0.036%) with similar risk reduction for ischemic events  [7] .
 The 2011 multispecialty Guidelines on the Management of Patients with Extracranial 
Carotid and Vertebral Artery Disease: Executive Summary recommended dual antiplatelet 
therapy with aspirin (81–325 mg daily) plus clopidogrel (75 mg daily) prior to and for a 
minimum of 30 days after carotid artery stent placement; for patients intolerant of clopi-
dogrel, ticlopidine (250 mg twice daily) may be substituted based on C level evidence  [8] . The 
current guidelines on carotid artery stent placement do not mention cilostazol as an alter-
native to clopidogrel  [9] . In the coronary circulation, cilostazol reduced the incidence of reste-
nosis after balloon angioplasty and bare metal stent placement compared with aspirin and 
clopidogrel or ticlopidine  [10–12] . Similarly, the combination of cilostazol and aspirin had 
lower rates of restenosis following carotid artery stent placement compared with aspirin and 
clopidogrel or ticlopidine in an observational study  [13] . We performed a phase I open-label, 
nonrandomized two-center prospective study, to determine the safety of 1-month treatment 
with aspirin (325 mg/day) and cilostazol (200 mg/day) following extracranial stent placement.
 Methods 
 We conducted a phase I open-label, nonrandomized two-center (Hennepin County Medical Center, 
Minneapolis, MN and University of Minnesota Medical Center, Minneapolis, MN) prospective study with the 
approval of the institutional review board of both hospitals. All subjects signed an informed consent prior to 
participating in the study. Each patient received aspirin (325 mg/day) and cilostazol (200 mg/day) for 3 days 
before extracranial stent placement. The two antiplatelet agents were continued for 1 month postprocedure 
and then aspirin (325 mg) daily monotherapy was continued thereafter. Study subjects were 18 years of age 
or older, with a baseline modified Rankin score of 0–2, who were scheduled to undergo extracranial internal 
carotid artery stent placement with or without balloon angioplasty for symptomatic or asymptomatic carotid 
artery stenosis. A distal embolic protection device was used with every stent placed. The internal carotid 
stenosis had to be greater than 50% and less than or equal to 99% as measured by the North American Symp-
tomatic Carotid Endarterectomy Trial (NASCET)  [14] . Subjects who received a carotid stent had high surgical 
risk features such as clinically significant cardiac disease (congestive heart failure, abnormal stress test, or 
need for open-heart surgery), severe pulmonary disease, contralateral carotid occlusion, contralateral 
laryngeal nerve palsy, previous radical neck surgery or radiation therapy to the neck, recurrent stenosis after 
endarterectomy, and age greater than or equal to 80 years  [15] . Also, stenting was preferred when there was 
a high carotid artery bifurcation, at the level of the C2 vertebra and above.
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 Subjects were excluded from participating in the study if they had a history of bleeding diathesis, 
including disorders treated by warfarin therapy (however, those who had received warfarin but had stopped 
taking the medication 3 days before the procedure and had an international normalized ratio less than 1.2 
were eligible for inclusion). Similarly, subjects were excluded if they had severe hypertension (defined as 
systolic blood pressure greater than 180 mm Hg or diastolic blood pressure greater than100 mm Hg, despite 
therapy), had a major surgery within the previous 6 weeks, or had a previous history of a hemorrhagic stroke. 
Pregnant patients or women who were breast-feeding were excluded from the study. Subjects were also 
excluded if they had gastrointestinal or genitourinary bleeding within the previous 30 days of treatment, had 
platelets less than 30,000, and/or had congestive heart failure.
 The primary efficacy end point was the 30-day composite occurrence of death, cerebral infarction, tran-
sient ischemic attack, and in-stent thrombosis requiring unplanned endovascular revascularization procedure. 
The primary safety end point was bleeding. Bleeding complications were classified as major, moderate, or 
minor according to criteria used by the Thrombolysis in Myocardial Infarction trial group  [16] . Major bleeding 
was defined as any intracranial hemorrhage or a decrease in hemoglobin level of less than 5 g/dL that resulted 
in hemodynamic compromise requiring treatment. Moderate bleeding was defined by the need for transfusion. 
Minor bleeding was defined as any decrease in hemoglobin level of 3 to 5 g/dL, not requiring transfusion or 
causing hemodynamic compromise. The age of the subjects, gender, medical comorbidities, length of intensive 
care stay (days), length of hospital stay (days), clinical indication for treatment, clinical presentation, and 
location of carotid stenosis were abstracted from the electronic medical record. The intraprocedural details 
regarding the stent deployed, whether pre- or post-balloon angioplasty was utilized as well as the balloon type, 
the posttreatment stenosis, and complications were abstracted from the medical record. Similarly, the follow-
up complications and 1-month modified Rankin scale scores were also documented for each patient.
 Statistical Analysis 
 The data is presented in a descriptive presentation. The mean value with standard deviation (SD) was 
presented for continuous variables including age and pre-stent and post-stent stenosis with or without 
angioplasty. The total number of immediate procedure-related and postprocedure follow-up complications 
were documented and counted. Postprocedure follow-up complications were defined as any complication 
that occurred after the immediate procedure and within the follow-up time period.
 Results 
 Twelve subjects (mean age ± SD, 66 ± 12 years; 9 men) were enrolled using the study 
protocol and underwent internal carotid artery stent placement with or without angioplasty 
with a distal embolic protection device. All the patients who received a carotid artery stent 
had stenosis secondary to extracranial atherosclerotic disease; there were no carotid stents 
placed for an arterial dissection. The procedure was performed in the right and left extra-
cranial internal carotid arteries in 7 (58%) and 5 (42%) subjects, respectively. All the subjects 
were treated using the Nitinol PRECISE ® PRO RX ® Stent system (Johnson and Johnson; New 
Jersey) except for one patient who was treated with an Xpert stent (Abbott; Illinois, USA). The 
decision to use the 4-mm Xpert stent (Abbott) was based on the size of the internal carotid 
artery. The pre-stent percent stenosis and post-stent percent stenosis represented as mean 
± SD were 79 ± 10% and 9 ± 10%, respectively. Pre-stent angioplasty was used in 5 subjects. 
Post-stent angioplasty was used in 5 subjects. There was one patient who received pre-angio-
plasty dilation of the stenotic lesion followed by post-stent angioplasty for further lesion 
dilation. One patient had stent placement alone, without pre- or post-angioplasty (see 
 Table 2 ). Patients 3 and 6 represent the same patient but the extracranial carotid arteries 
were treated at separate time points, respectively, and were treated as two subjects (see 
 Table 1 ). Other comorbidities among study subjects included: hypertension in 10 (83%), 
hyperlipidemia in 9 (75%), atrial fibrillation in 2 (17%), diabetes mellitus in 5 (42%), history 
of recent ischemic stroke and/or TIA in 7 (58%), congestive heart failure in 3 (25%), and 
tobacco dependence in 4 (33%) subjects.
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 All of the study subjects who successfully followed the study protocol completed the study 
without any change in their pre- and posttreatment modified Rankin score and did not expe-
rience any intracerebral hemorrhage, systemic bleeding complications, ischemic stroke, tran-
sient ischemic attack, or in-stent thrombosis at the 1-month and 3-month follow-up. Prior to 
stent placement, one patient discontinued cilostazol after the first dose secondary to nonspe-
cific dizziness. There was a protocol deviation in one patient due to concurrent use of enoxa-
parin (1 mg/kg twice daily) in addition to aspirin and cilostazol. The patient suffered a fatal 
symptomatic intracerebral hemorrhage following successful stent placement on postpro-
cedure day 1. A third patient was successfully enrolled in the study but the cilostazol was 
discontinued by her cardiologist 5 days after the successful and uncomplicated stent placement.
 Table 1.  Baseline and angiographic characteristics of the study subjects recruited in the phase I trial
Patient Age, 
years/
sex
Clinical presentation Cardiovascular risk factors Lesion 
site
Pre-
treatment 
stenosis, %
1 63/M 1 month prior to stenting had 
multiple MRI-proven subacute and 
acute infarcts in right cerebral 
hemisphere; refused CEA
DM type II, hypertension Right ICA 90
2 60/M Multiple spells of amaurosis fugax of 
right eye
Occluded left ICA, HTN, HPLD, severe 
COPD
Right ICA 75
3 56/M Acute ischemic stroke with right-side 
hemiparesis and dysarthria
Nine years prior had neck radiation for 
Hodgkin’s lymphoma; HTN; tobacco 
dependent
Left ICA 85
4 75/F TIA: sensory alteration of the right 
side of the body
HTN, A. Fib., CHF, DM type II, HLPD Left ICA 80
5 50/M Acute ischemic stroke with left sided 
hemiparesis
HTN, HLPD Right ICA 70
6 56/M Asymptomatic Acute ischemic stroke secondary to a 
severe left ICA 85% stenosis 2 months 
prior to stenting; 9 years prior had neck 
radiation for Hodgkin’s lymphoma; HTN; 
tobacco dependent
Right ICA 85
7** 63/F TIA: left hand weakness a week prior 
to stenting
A. Fib., HTN, CHF, DM type II Right ICA 80
8** 72/M Amaurosis fugax of the left eye HTN, HLPD, coronary artery disease, DM 
type II
Left ICA 60
9 91/F TIA: intermittent word finding 
difficulties
HTN, DM type II, ischemic stroke (2004); 
coronary artery disease with C ABG
Left ICA 75
10 57/M Right corona radiata ischemic stroke 
with left hemiparesis
HTN, DM type II Left ICA 99
11 71/M Asymptomatic HTN, HPLD, right ICA stenosis treated 
with carotid stent previously, CHF
Right ICA 80
12 81/M Acute ischemic stroke with left arm 
and leg hemiparesis
Had poor medical follow-up. Did not have 
any prior medical history
Right ICA 70
 Patients No. 3 and 6 represent the same patient treated at different time points. The 2 subjects with asterisks were not included in 
the study analysis because they did not complete the study. A. Fib., atrial fibrillation; CABG, coronary artery bypass graft; CEA, carotid 
endarterectomy; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; F, female; HLPD, 
hyperlipidemia; HTN, hypertension; ICA, internal carotid artery; M, male; MRI, magnetic resonance imaging; TIA, transient ischemic 
attack.
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 Discussion 
 Ischemic stroke can occur during or after extracranial internal carotid artery stent 
placement in rates varying from 4 to 10% depending on patient characteristics due to throm-
boembolic complications  [17] . Clopidogrel and aspirin are the most commonly utilized anti-
platelet medications prescribed prior to and following extracranial internal carotid artery 
stent placement to prevent in-stent thrombosis. This is the first phase I study in the United 
States that demonstrated the feasibility of using cilostazol and aspirin dual antiplatelet 
therapy to prevent in-stent thrombosis following internal carotid artery stenting. When 
adhering to the treatment regiment, cilostazol and aspirin appeared to be a safe treatment 
alternative to aspirin and clopidogrel, but such an observation requires further prospective 
studies to demonstrate efficacy in prevention of ischemic events. There are few reports that 
have examined the efficacy of dual antiplatelet treatment with aspirin and cilostazol specifi-
cally following carotid stent placement, with the majority of studies focusing on patients with 
coronary artery disease who have coronary stents placed  [18] .
 Table 2. Procedural information and clinical outcomes in study subjects
Patient Angioplasty performed Stent (type, 
size)
Post- 
treatment 
stenosis, 
%
Intra-
procedural 
com-plication
Post 
procedure 
death
Bleeding compli-
cations, stroke, TIA, stroke 
or in-stent thrombosis/ 
occlusion at 1 month 
posttreatment
ICU/total 
hospital 
stay, days
1 month 
modified 
Rankin scale 
score
1 Mavericka, 
3 mm × 20 mm
Precise,
7 mm × 40 mm
20 0 0 0 1/1 0
2 Aviatora,
4 mm × 20 mm; 
Aviatorb,
5 mm × 20 mm
Precise,
8 mm × 30 mm
10 0 0 0 1/1 0
3 Viatracb,
4 mm × 20 mm
Precise,
7 mm × 30 mm
10 0 0 0 2/9 0
4 Aviatora,
4.0 mm × 30 mm
Precise,
7 mm × 30 mm
25 0 0 0 1/1 0
5 Viatracb,
4.5 mm × 20 mm
Precise,
8 mm × 30 mm
0 0 0 0 1/3 2 
(baseline)
6 Viatracb,
4 mm × 20 mm
Precise,
7 mm × 40 mm
20 0 0 0 1/1 0
7** Viatraca,
4 mm × 30 mm
Precise,
7 mm × 30 mm
0 0 1 – 1/2 6
8** None Xpert,
4 mm × 20 mm
0 0 0 0 1/1 0
9 Aviatora,
4.5 mm × 15 mm
Precise,
7 mm × 40 mm
20 0 0 0 1/1 0
10 Mavericka,
3 mm × 20 mm 
Precise,
7 mm × 30 mm
0 0 0 0 1/2 0
11 Aviatorb,
5 mm × 30 mm
Precise,
6 mm × 40 mm
0 0 0 0 1/1 0
12 Viatracb,
5 mm × 30 mm 
Precise,
7 mm × 40 mm
0 0 0 0 1/7 1
The 2 subjects with asterisks were not included in the study analysis because they did not complete the study.
a Pre-stent balloon. b Post-stent balloon. 
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 Aspirin and clopidogrel have been demonstrated to be safe in the setting of extracranial 
carotid artery stenting. The IDEALCAST (Investigation on Devices and Antiplatelet Therapy 
for Carotid Artery Stenting) investigators conducted a multicenter prospective observational 
study on the onset of vascular events after carotid artery stenting in an effort to find out the 
efficacy and safety of carotid artery stenting in Japan and to investigate the effects of anti-
platelet drugs administered before and after carotid artery stenting on efficacy and safety of 
carotid artery stenting. A total of 949 patients with extracranial carotid artery stenosis were 
enrolled and 934 had carotid artery stents placed with antiplatelet drugs and were followed 
for 1 year. The primary end point (incidence of the first event of death, ischemic stroke, 
hemorrhagic stroke, transient ischemic attack, myocardial infarction, or serious hemorrhage 
within 1 year after enrollment) was observed in 69 patients (7.4%) within 30 days of 
enrollment and in 40 patients (4.3%) between 31 days and 1 year after enrollment. The 
choice of antiplatelet agents in the periprocedural period was up to the investigators. The 
incidence of the first event for aspirin and cilostazol was significantly lower than that for 
aspirin and clopidogrel ( p = 0.01), aspirin and clopidogrel and cilostazol ( p = 0.01), and anti-
platelet monotherapy ( p ˂ 0.01)  [9] .
 One of the limitations of bare metal stent implantation is the restenosis secondary to 
intimal hyperplasia within or adjacent to the stent  [19, 20] . Cilostazol has been found to reduce 
neointimal formation in balloon-injured rat carotid arteries and inhibits restenosis after percu-
taneous transluminal coronary angioplasty  [21, 22] . Takayama et al.  [13] performed a retro-
spective, multicenter trial of 62 carotid artery lesions in 60 patients, studying the restenosis 
rate following carotid artery stenting with the carotid wall stent. There was a cilostazol (aspirin, 
100 mg, and cilostazol, 200 mg;  n = 30) and non-cilostazol group (aspirin, 100 mg, and clopi-
dogrel, 75 mg [ n = 29], or ticlopidine, 100 mg [ n = 2] or 200 mg [ n = 1]). The two antiplatelet 
medications were given 1 week preoperatively and continued for at least 3 months postopera-
tively. The patients were followed at 3 and 6 months postoperatively with an angiographic 
study. Takayama et al.  [13] found that there were 5 cases of asymptomatic restenosis (8.3%) (4 
were from the aspirin and clopidogrel group, and 1 was from the ticlopidine group) but none 
in the cilostazol treatment group, and the difference was statistically significant ( p = 0.0239).
 This study was intended to demonstrate the safety and feasibility of the addition of cilo-
stazol to aspirin prior to and following extracranial carotid artery stenting, but there are limi-
tations. One limitation of the study is the small sample size and its open-label design. The 
subjects were not randomized with a comparator group, and the results may not be represen-
tative of patients with characteristics different from the inclusion and exclusion criteria used.
 Conclusion 
 The use of cilostazol and aspirin for internal carotid artery stent placement appears to be 
safe, but protocol compliance needs to be emphasized. Further studies are required to analyze 
the effectiveness and role of cilostazol in neurointerventional procedures.
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